ER-100 FDA Clearance | First Epigenetic Reprogramming Human Trial

On January 28, 2026, the U.S. Food and Drug Administration cleared Life Biosciences' Investigational New Drug (IND) application for ER-100, a gene therapy using an adeno-associated virus (AAV2) vector to deliver three Yamanaka transcription factors, OCT4, SOX2, and KLF4 (OSK), for controlled, partial epigenetic reprogramming in retinal ganglion cells. The clearance marks the first human clinical trial of partial epigenetic reprogramming for cellular rejuvenation in any disease indication. The Phase 1 trial (NCT07290244) focuses on safety and tolerability in adults with primary open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), with vision assessments as secondary endpoints.

What the FDA Cleared in the ER-100 IND Application

The FDA authorized ER-100 as an investigational epigenetic therapy candidate for age-related optic neuropathies, permitting Life Biosciences to proceed with first-in-human dosing under the trial protocol. The cleared IND specifies the following key elements:

Element	Detail
Vector and Payload	Modified AAV2 vector delivering inducible OSK (OCT4, SOX2, KLF4) genes
Mechanism	Controlled OSK expression restores methylation patterns and gene function in aged or damaged retinal ganglion cells
Administration	Single intravitreal injection with systemic oral doxycycline for induction control
Indications	Primary open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION)
Trial Design	Phase 1 first-in-human, single-dose, sequential cohorts with dose escalation in OAG, then expansion in NAION

The clearance follows preclinical data in mice and non-human primates showing restored vision, increased nerve axon survival, and improved electrical signaling without altering genomic DNA, per Life Biosciences platform data.

AAV2-OSK Delivery and Partial Reprogramming Mechanism | How ER-100 Works

ER-100 uses an AAV2-OSK construct to express OCT4, SOX2, and KLF4 transiently under doxycycline (Dox) control. OSK expression switches on via oral doxycycline administration and ceases when withdrawn, giving clinicians direct control over the reprogramming window.

This partial reprogramming approach achieves three critical outcomes:

Methylation pattern modification without triggering full cellular dedifferentiation
Targeted retinal ganglion cell (RGC) rejuvenation in cells affected by aging, intraocular pressure, or ischemic injury
Deliberate c-MYC exclusion, reducing oncogenic potential compared to full OSKM (four-factor) protocols

Preclinical Outcomes from Life Biosciences Data

Metric	Result
Mouse glaucoma models	Restored vision confirmed
Naturally aged mice	Improved visual function
Optic nerve crush injury	Increased nerve regeneration
NHP NAION models	Enhanced visual function and axon survival vs. controls
Genomic integrity	No alteration of genomic DNA sequence confirmed
Yamanaka factors delivered	3 (OSK, excludes c-MYC)
Species studied	2 (mouse and non-human primate)
Genomic edits	0 (epigenetic only, no DNA sequence changes)

Target Diseases | Open-Angle Glaucoma and NAION Patient Populations

Both conditions feature age-related retinal ganglion cell dysfunction, making them logical first test cases for localized epigenetic rejuvenation.

Primary Open-Angle Glaucoma (OAG)

OAG involves progressive optic nerve damage from elevated intraocular pressure, producing chronic, irreversible RGC loss and visual field defects. Existing treatments reduce intraocular pressure but do not address the underlying neurodegeneration or epigenetic aging of retinal ganglion cells. An estimated 80 million people worldwide live with glaucoma, and it remains a leading cause of irreversible blindness. ER-100 targets the disease at the cellular aging level rather than the pressure management level, representing a fundamentally different therapeutic approach.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION causes sudden, painless vision loss from reduced blood flow to the optic nerve head. It is the most common acute optic neuropathy in adults over 50, with an estimated annual incidence of 2.3 to 10.2 per 100,000 in the general population. No approved treatment exists for NAION, making it a compelling target for a regeneration-focused approach. The absence of any FDA-approved NAION therapy gives ER-100 a potential first-mover pathway in an unmet-need indication.

NCT07290244 Phase 1 Trial Design | Cohorts, Endpoints, Safety Parameters

Parameter	Detail
Cohort 1 (OAG)	Ascending single doses, safety, tolerability, maximum tolerated dose
Cohort 2 (NAION)	Confirmed safe dose from Cohort 1 administered to NAION patients
Primary endpoint	Safety and tolerability of a single intravitreal dose
Secondary endpoints	Immune responses, visual acuity, visual field, optical coherence tomography (OCT), electrophysiology

No efficacy claims are primary endpoints in Phase 1. Vision improvement results, if observed, will be hypothesis-generating for Phase 2 design, not the basis for regulatory approval at this stage.

Preclinical Foundation | Multi-Year Program Leading to IND Clearance

The IND submission was supported by a multi-year preclinical program. Key data points reviewed by the FDA include:

Controlled expression: Doxycycline-regulated induction confirmed in primate retinal tissue with clean shutoff on withdrawal
Methylation restoration: AAV2-OSK measurably reversed age-associated methylation patterns toward a younger epigenetic signature
Visual recovery: Statistically significant improvement in visual acuity and electrophysiology in NHP NAION models vs. controls
Genomic integrity: No off-target edits, chromosomal instability, or tumor formation across all preclinical cohorts

Life Biosciences' Chief Scientific Officer stated in the press release that primate data “provided the confidence that controlled, transient OSK expression can safely restore cellular function in the aging retina without the safety liabilities of full reprogramming.”

2026 Clinical Milestones | Timeline from IND to Phase 2 Decision

Timeline	Milestone
Q1 2026	First patient dosing, OAG Cohort 1 dose escalation
Q2-Q3 2026	Dose escalation completion and dose selection
Q3 2026	NAION cohort initiation
Q4 2026	Preliminary safety and immune response readout
2027	Phase 2 design decisions pending Phase 1 outcomes

From Nobel Prize to Clinic | The 20-Year Path of Yamanaka Factor Research

The significance of ER-100's IND clearance lies in what it precisely is, and what it is not. This is not a systemic youth serum. It is not an FDA endorsement of age reversal. It is a targeted gene therapy, delivered to one eye, for two specific degenerative conditions, in a safety trial with no efficacy claims.

What it does establish, for the first time, is that a regulatory authority has reviewed the science of partial epigenetic reprogramming and judged it safe enough to test in humans. The Nobel Prize science behind iPSCs has taken roughly two decades to reach a first human injection.

Year	Milestone
2006	Shinya Yamanaka discovers iPSC reprogramming factors (OSKM), Nobel Prize awarded 2012
2013-2019	Partial reprogramming concept developed in mouse models (Salk Institute, Juan Carlos Izpisua Belmonte lab)
2020	David Sinclair lab (Harvard) demonstrates vision restoration in aged mice using OSK, published in Nature
2020-2023	Life Biosciences preclinical program: mouse glaucoma models, NHP NAION studies
January 28, 2026	FDA clears ER-100 IND, first human epigenetic reprogramming trial authorized
Q1 2026	Phase 1 enrollment begins, OAG dose escalation cohort

When the first human dose of OSK arrives via intravitreal injection for a glaucoma patient rather than a systemic longevity protocol, the path from Nobel discovery to clinic stays firmly on the optic nerve. This milestone connects directly to broader themes in ObjectWire's Bio-Hacking and Longevity coverage and the adjacent clinical science of immune modulation for organ longevity covered in the Eledon Pharmaceuticals (ELDN) overview.

Why Partial Reprogramming Differs from Full iPSC Protocols | Safety Distinction

Full OSKM reprogramming (using all four Yamanaka factors including c-MYC) resets cells to a pluripotent state, effectively turning them back into stem cells. While powerful in laboratory settings, full reprogramming carries substantial oncogenic risk because c-MYC is a well-characterized proto-oncogene, and complete dedifferentiation can produce teratomas (tumors containing multiple tissue types).

ER-100's partial reprogramming approach differs in three critical ways:

Three factors, not four: OSK excludes c-MYC, the primary oncogenic driver in the Yamanaka cocktail
Transient expression, not permanent: Doxycycline-controlled activation means the reprogramming window has a defined on/off switch
Localized delivery, not systemic: Intravitreal injection limits OSK expression to the eye, avoiding whole-body exposure

This distinction matters for the regulatory path. The FDA has approved multiple AAV-based gene therapies for ocular indications, including Luxturna (voretigene neparvovec) for RPE65-associated retinal dystrophy. ER-100's delivery mechanism follows an established regulatory precedent for intravitreal AAV therapies, even though the payload (epigenetic reprogramming factors rather than a replacement gene) is entirely novel.

Competitive Landscape | Other Epigenetic Reprogramming Programs in Development

ER-100 is not the only epigenetic reprogramming program in development, but it is the first to receive FDA IND clearance for human dosing. Other notable programs include:

Altos Labs (founded 2022, $3 billion initial funding): pursuing systemic reprogramming research with Yamanaka factor variants, no IND filed as of January 2026
NewLimit (co-founded by Brian Armstrong, Coinbase CEO): focused on epigenetic reprogramming for T-cell rejuvenation, preclinical stage
Retro Biosciences (Sam Altman-backed): targets cellular reprogramming for multiple age-related diseases, preclinical stage
Turn Biotechnologies: uses proprietary ERA (Epigenetic Reprogramming of Aging) platform with mRNA delivery rather than AAV, preclinical dermatology applications
Shift Bioscience: computational approach to identifying optimal partial reprogramming protocols, preclinical

Life Biosciences' advantage is specificity. While competitors pursue broader systemic applications, ER-100 chose the narrowest viable indication (two ocular diseases) with the most established delivery route (intravitreal AAV), maximizing the probability of regulatory clearance at the cost of addressable market size. The strategy prioritized getting into humans first over targeting the largest possible patient population.

Primary Sources and Key Documents

ClinicalTrials.gov, NCT07290244
Life Biosciences Platform Data
Life Biosciences Press Release, January 28, 2026
Nature Biotechnology brief, February 2026
BIO Summit 2026 company presentation

ER-100 FDA Clearance | First Human Trial of Partial Epigenetic Reprogramming for Optic Neuropathies